| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 2 mg | 8 years | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 80 mg | 2 mg | 9 years | — |
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 2 mg | 2409 days | — |
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · combination of antioxidants and zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 2 mg | 2409 days | — |
| Therapeutic evaluation of zinc and copper supplementation in acute diarrhea in children: double blind randomized trial 2005 · zinc and copper supplementation · Children aged 6 months to 59 months with acute diarrhea in an urban hospital | 40 mg | 5 mg | — | 102 |
| Effects of fortified milk on morbidity in young children in north India: community based, randomised, double masked placebo controlled trial 2007 · fortified milk · Children aged 1–3 years in a peri-urban settlement in north India | 7.8 mg | 270 mcg | 1 year | 316 |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 2 mg | 8 years | — |
| Effects of multimicronutrient supplementation on helminth reinfection: a randomized, controlled trial in Kenyan schoolchildren 2003 · multimicronutrient supplementation · Schoolchildren in Nyanza Province, Kenya; age and sex not specified | 20 mg | 2 mg | 335 days | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 30 mg | 2 mg | — | — |
| Effect of micronutrient supplementation on diarrhoeal disease among stunted children in rural South Africa 2009 · multiple micronutrients · children aged 6–24 months; three cohorts: HIV-infected children, HIV-uninfected children born to HIV-infected mothers, and HIV-uninfected children born to HIV-uninfected mothers | 10 mg | 600 mcg | 548 days | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 80 mg | 2 mg | 9 years | — |
| Effects of therapeutic zinc supplementation for diarrhea and two preventive zinc supplementation regimens on the incidence and duration of diarrhea and acute respiratory tract infections in rural Laotian children: A randomized controlled trial 2020 · MNP group · Children aged 6–23 months in rural Laos | 10 mg | 560 mcg | 40 weeks | 852 |
| Effect of preventive supplementation with zinc and other micronutrients on non-malarial morbidity in Tanzanian pre-school children: a randomized trial 2012 · Multi-nutrients with zinc · Children aged 6–60 months with height-for-age z-score ≤−1.5 SD, in rural Tanzania | 10 mg | 340 mcg | — | 151 |
| Zinc and copper supplementation in acute diarrhea in children: a double-blind randomized controlled trial 2009 · zinc and copper (Zn+Cu) arm · Children aged 6–59 months with acute watery or bloody diarrhea | 2 mg/kg | 0.2 mg/kg | 2 weeks | 273 |
| Zinc supplementation sustained normative neurodevelopment in a randomized, controlled trial of Peruvian infants aged 6-18 months 2014 · zinc, iron, and copper supplement · Infants aged 6–18 months | 10 mg | 500 mcg | 1 year | — |
| Reported zinc, but not copper, intakes influence whole-body bone density, mineral content and T score responses to zinc and copper supplementation in healthy postmenopausal women 2011 · 600 mg Ca plus 2 mg Cu and 12 mg Zn · Healthy postmenopausal women aged 51–80 years | 12 mg | 2 mg | 2 years | 112 |
| Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals 1994 · trace minerals only · Healthy postmenopausal women, mean age 66 years | 15 mg | 2.5 mg | 2 years | — |
| Micronutrient fortified milk improves iron status, anemia and growth among children 1-4 years: a double masked, randomized, controlled trial 2010 · Micronutrient-fortified milk (MN group) · Children aged 1–4 years in India; many had anemia, iron deficiency, or growth faltering | 7.8 mg | 270 mcg | 1 year | 316 |
| Effect on longitudinal growth and anemia of zinc or multiple micronutrients added to vitamin A: a randomized controlled trial in children aged 6-24 months 2010 · Multiple micronutrients · Children enrolled at 6 months and followed to 24 months in rural South Africa; HIV-infected and HIV-uninfected children, both sexes | 10 mg | 600 mcg | 548 days | 126 |
| Effects of Low-Dose Dairy Protein Plus Micronutrient Supplementation during Resistance Exercise on Muscle Mass and Physical Performance in Older Adults: A Randomized, Controlled Trial 2018 · ExPM (resistance exercise plus low-dose dairy protein and micronutrient supplementation) · Adults aged 65–80 years, non-disabled and not exercising regularly | 8 mg | — | 12 weeks | 40 |
| TOZAL Study: an open case control study of an oral antioxidant and omega-3 supplement for dry AMD 2007 · Sham MCS and nutritional supplement · Adults aged 50–90 with dry age-related macular degeneration in at least one eye | 69.6 mg | 1.6 mg | 24 weeks | 37 |
| Carotenoids and antioxidants in age-related maculopathy italian study: multifocal electroretinogram modifications after 1 year 2008 · treated AMD (T-AMD) group · Patients with nonadvanced age-related macular degeneration; mean age 69.4 years | 22.5 mg | 1 mg | 1 year | 15 |
| The effects of antioxidant vitamin supplementation on expiratory flow rates at rest and during exercise 2015 · antioxidant vitamin supplementation (AVS) · healthy nonsmoking adults, 5 men and 5 women, consuming fewer than 5 servings of fruit and vegetables per day | 7.5 mg | 1 mg | 4 weeks | 10 |
| [Vitrum osteomag in prevention of osteoporosis in postmenopausal women: results of the comparative open multicenter trial] 2004 · Group 1: Vitrum Osteomag · Postmenopausal women with osteopenia; age range not reported | 15 mg | 2 mg | 1 year | 125 |
| Spinal bone loss in postmenopausal women supplemented with calcium and trace minerals 1994 · calcium plus trace minerals · Healthy postmenopausal women, mean age 66 years | 15 mg | 2.5 mg | 2 years | — |
| The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7 2002 · zinc · Adults aged 55–80 years with early-to-late age-related macular degeneration | 80 mg | 2 mg | 5 years | — |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 2 (Vitalux AREDS) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 25 mg | 1 mg | — | 10 |
| Zinc supplementation inhibits complement activation in age-related macular degeneration 2014 · Zinc and copper supplement · Adults with age-related macular degeneration; mean age 73.9 years | 50 mg | 1 mg | 90 days | 72 |
| The effect of five-year zinc supplementation on serum zinc, serum cholesterol and hematocrit in persons randomly assigned to treatment group in the age-related eye disease study: AREDS Report No. 7 2002 · antioxidants and zinc · Adults aged 55–80 years with early-to-late age-related macular degeneration | 80 mg | 2 mg | 5 years | — |
| A moderately high intake compared to a low intake of zinc depresses magnesium balance and alters indices of bone turnover in postmenopausal women 2004 · Low dietary copper and high-zinc period · Postmenopausal women, mean age 64.9 years; no other condition stated | 53 mg | 1 mg | 90 days | — |
| A moderately high intake compared to a low intake of zinc depresses magnesium balance and alters indices of bone turnover in postmenopausal women 2004 · High dietary copper and high-zinc period · Postmenopausal women, mean age 64.9 years; no other condition stated | 53 mg | 3 mg | 90 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS zinc only · Adults aged 55–80 with early or more advanced age-related macular degeneration | 80 mg | 2 mg | 5 years | — |
| Including 60 mg Elemental Iron in a Multiple Micronutrient Supplement Blunts the Increase in Serum Zinc after 12 Weeks of Daily Supplementation in Predominantly Anemic, Nonpregnant Cambodian Women of Reproductive Age 2019 · MMN · Predominantly anemic, nonpregnant women aged 18–45 years | 15 mg | 2 mg | 12 weeks | 202 |
| The effects of a lipid-based nutrient supplement and antiretroviral therapy in a randomized controlled trial on iron, copper, and zinc in milk from HIV-infected Malawian mothers and associations with maternal and infant biomarkers 2018 · LNS · HIV-infected lactating women in Malawi | 19 mg | 300 mcg | 28 weeks | 185 |
| Mineral status of non-anemic Peruvian infants taking an iron and copper syrup with or without zinc from 6 to 18 months of age: a randomized controlled trial 2013 · iron + copper + zinc group · Non-anemic Peruvian infants randomized at 6 months of age, born at term and weighing more than 2500 g; followed until 18 months | 10 mg | 500 mcg | 1 year | 129 |
| The effects of a lipid-based nutrient supplement and antiretroviral therapy in a randomized controlled trial on iron, copper, and zinc in milk from HIV-infected Malawian mothers and associations with maternal and infant biomarkers 2018 · ARV + LNS · HIV-infected lactating women in Malawi | 19 mg | 300 mcg | 28 weeks | 90 |
| Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects 2003 · 100 mg Fe as ferrous gluconate · 11 adults with an ileostomy; mean age 55 ± 9 years; sex not specified | 12 mg | 3 mg | 1 day | 11 |
| Iron supplements inhibit zinc but not copper absorption in vivo in ileostomy subjects 2003 · 400 mg Fe as ferrous gluconate · 11 adults with an ileostomy; mean age 55 ± 9 years; sex not specified | 12 mg | 3 mg | 1 day | 11 |
| Dose-response trial of prophylactic zinc supplements, with or without copper, in young Ecuadorian children at risk of zinc deficiency 2008 · 10 mg Zn + 0.5 mg Cu as copper sulfate · Ecuadorian children aged 12–30 months at baseline with length-for-age z scores below −1.3, at risk of zinc deficiency | 10 mg | 500 mcg | 26 weeks | — |
| Antenatal Multiple Micronutrient Supplementation Compared to Iron-Folic Acid Affects Micronutrient Status but Does Not Eliminate Deficiencies in a Randomized Controlled Trial Among Pregnant Women of Rural Bangladesh 2019 · MM · Pregnant women aged 12–45 years in rural Bangladesh | 12 mg | 1 mg | 165 days | 749 |
| Including 60 mg Elemental Iron in a Multiple Micronutrient Supplement Blunts the Increase in Serum Zinc after 12 Weeks of Daily Supplementation in Predominantly Anemic, Nonpregnant Cambodian Women of Reproductive Age 2019 · Fe + MMN · Predominantly anemic, nonpregnant women aged 18–45 years | 15 mg | 2 mg | 12 weeks | 206 |
| Newborn micronutrient status biomarkers in a cluster-randomized trial of antenatal multiple micronutrient compared with iron folic acid supplementation in rural Bangladesh 2020 · MM · Pregnant women in rural Bangladesh; age range not specified; no disease condition specified | 12 mg | 1 mg | — | 176 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · MMN group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 30 mg | 4 mg | 184 days | 75 |
| mRNA Levels of Placental Iron and Zinc Transporter Genes Are Upregulated in Gambian Women with Low Iron and Zinc Status 2017 · PE+MMN group · Pregnant women aged 18–45 years with singleton pregnancies under 20 weeks in rural Gambia | 30 mg | 4 mg | 184 days | 75 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel half-dose (single softgel) · Healthy adults aged 18–45 years, women and men | 34.8 mg | — | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel full-dose (two softgels) · Healthy adults aged 18–45 years, women and men | 69.6 mg | — | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men | 69.6 mg | — | 1 day | 15 |
| A moderately high intake compared to a low intake of zinc depresses magnesium balance and alters indices of bone turnover in postmenopausal women 2004 · Low dietary copper and low-zinc period · Postmenopausal women, mean age 64.9 years; no other condition stated | 3 mg | 1 mg | 90 days | — |
| A moderately high intake compared to a low intake of zinc depresses magnesium balance and alters indices of bone turnover in postmenopausal women 2004 · High dietary copper and low-zinc period · Postmenopausal women, mean age 64.9 years; no other condition stated | 3 mg | 3 mg | 90 days | — |
| Multiple micronutrient supplementation improves micronutrient status in primary school children in Hai Phong City, Vietnam: a randomised controlled trial 2021 · intervention · Children aged 6–9 years, apparently healthy, in rural Hai Phong City, Vietnam; included undernourished, normal-weight, and overweight/obese children | 10 mg | 560 mcg | 22 weeks | 175 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 25 mg | 1 mg | — | 10 |
| Prophylactic iron supplementation in pregnant women in Norway 2001 · 15 mg iron daily · Non-anaemic pregnant women, allocated at about 10 weeks of pregnancy | 10 mg | 2 mg | — | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 80 mg | 2 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 80 mg | 2 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 80 mg | — | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 25 mg | — | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation without β-carotene and with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 25 mg | — | 5 years | — |